Aims: Relapsed or refractory multiple myeloma (RRMM) remains a therapeutic challenge due to treatment resistance, comorbidities, and limited options after multiple therapy lines. Carfilzomib, a second-generation proteasome inhibitor, has demonstrated efficacy when administered once weekly at 70 mg/m² in combination with dexamethasone (wKd70), offering a convenient and effective alternative to twice-weekly schedules.We conducted a retrospective analysis of 32 RRMM patients treated with wKd70 between 2018 and 2023 at a single referral center. Methods: Thirty-two RRMM patients were analyzed retrospectively. Patients with RRMM who received at least one course of carfilzomib at a dose of 70 mg/m² (administered on days 1, 8, and 15 of 28-day cycles) in combination with dexamethasone 40 mg/week were included in the study. Results: The median age was 57.5 years (range: 43–75), and patients had received a median of three prior therapy lines. The overall response rate (ORR) was 62.1% . Median progression-free survival (PFS) was 16 months, and median overall survival (OS) was 51 months . Prior autologous stem cell transplantation was associated with significantly improved PFS and OS. Adverse events were common but mostly mild (grades 1–2) forms. Conclusion: Our findings support wKd70 as an effective and well-tolerated treatment option for RRMM, even in heavily pretreated patients. The favorable survival outcomes compared to historical trials suggest a role for earlier use of this regimen.
Objective: Acute leukemia often involves comorbidities, impacting treatment decisions and patient outcomes. Clinicians commonly use the Charlson Comorbidity Index (CCI) and the Hematopoietic Stem Cell Transplantation Comorbidity Index (HCT-CI) to assess their influence. However, their effectiveness in predicting survival and non-relapse mortality (NRM) in acute leukemia patients under 65 undergoing allogeneic stem cell transplantation remains unclear. Patients and Methods: We conducted a retrospective single-center analysis on adults diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). The study included 35 patients, comprising 16 AML and 19 ALL cases. Patients were categorized based on age-adjusted HCT-CI and CCI scores. Results: The 2-year NRM rate was determined to be 51.4%. Statistical analysis found no significant associations between age-adjusted CCI (p=0.217) and age-adjusted HCT-CI (p=0.102) with NRM. However, median overall survival significantly varied based on risk levels (p=0.003), HCT-CI groups (p=0.009), and CCI groups (p=0.011). Conclusion: Using age-adjusted HCT-CI and CCI for comorbidity scoring in initial assessment of acute leukemia patients and those under 65 shows promise. However, these indices were ineffective in predicting NRM, emphasizing the importance of considering other significant pre-transplant factors like genetic risk, conditioning regimens, and donor type.
Objectives: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with approximately one-third of patients presenting with extranodal involvement. The gastrointestinal (GI) tract is the most commonly affected extranodal site. This retrospective study aimed to evaluate the clinical characteristics and treatment outcomes of patients diagnosed with GI-DLBCL at a tertiary care hospital between 2015 and 2024. Patients and Methods: Data of patients diagnosed with GI-DLBCL were retrospectively collected from electronic medical records. Patients with lymphoma subtypes other than DLBCL were excluded from the study. Results: A total of 35 patients were included. The median age at diagnosis was 57 years, and 48.6% were male. The most frequent histologic subtype was “DLBCL, not otherwise specified (NOS)”. The stomach was the most common site of extranodal involvement. Two-thirds of the patients presented with advanced-stage disease. Rituximab-based therapies including cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab (R-CHOP) were administered as first-line treatment in 82.9% of patients, and a complete response was achieved in 71.4%. At a median follow-up of 45 months, median progression-free survival and overall survival had not yet been reached. Conclusion: Despite a high rate of advanced-stage disease, R-CHOP treatment achieved high response rates and durable survival. Molecular profiling may help better understand the biological heterogeneity of GI-DLBCL.